Drug Safety Diligence Demands Proactive, Ongoing Assessment – FDLI Panel
To stay afloat with heightened and still-evolving drug safety standards, drug firms must investigate their products for safety signals even in the absence of any indication of a problem, according to a panel at an April 22 conference of the Food & Drug Law Institute
You may also be interested in...
Providing protections to those who follow guidelines should appeal to both Republicans and Democrats, the former McCain campaign advisor says.
Market withdrawal of Genentech's psoriasis drug Raptiva (efalizumab) shows FDA under new leadership acting decisively on drug safety - especially in cases where comparable treatment alternatives exist
While the Supreme Court's landmark ruling in Wyeth v. Levine dashes pharmaceutical industry hopes for broad protection from product liability lawsuits, it will not trigger any sea change in litigation. Instead, the opinion seems likely to maintain the status quo and restrict the situations in which companies can claim they provided adequate warning of a drug's risks